CFM
AZN icon

Catalyst Funds Management’s AstraZeneca AZN Stock Holding History

Catalyst Funds Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.48M Sell
44,699
-14,185
-24% -$2.67M 0.48% 46
2026
Q1 		$9.09M Buy
58,884
+51,884
+741% +$10M 1.54% 6
2025
Q4 		$1.29M Sell
7,000
-1,050
-13% -$184K 0.3% 83
2025
Q3 		$1.24M Buy
+8,050
New +$1.22M 0.19% 120

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Catalyst Funds Management's AZN Position: Q2 2026 in Review

Catalyst Funds Management reduced its AstraZeneca (AZN) stake by 24% in Q2 2026, selling an estimated $2.67M and leaving 44,699 shares worth $8.48M. The position accounts for 0.48% of the portfolio, ranked #46.

Catalyst Funds Management first reported a position in AZN in Q3 2025 and has held it in 4 quarters since. The position peaked at $9.09M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Catalyst Funds Management held 44,699 shares of AstraZeneca worth $8.48M as of Q2 2026.
  • Catalyst Funds Management sold 14,185 AstraZeneca shares in Q2 2026, an estimated $2.67M.
  • AstraZeneca made up 0.48% of Catalyst Funds Management's portfolio in Q2 2026, its #46 holding.
  • Catalyst Funds Management first reported a position in AstraZeneca in Q3 2025 and has held it in 4 quarters since.
  • Catalyst Funds Management's AstraZeneca position peaked at $9.09M in Q1 2026.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.